UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 285

Sortiert nach

HCV‐Positive Donor Organs in Solid Organ Transplantation: “Mind the Gap!”

American journal of transplantation, 2017-11, Vol.17 (11), p.2755-2756

2017

Volltextzugriff (PDF)

Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension

Journal of viral hepatitis, 2017-10, Vol.24 (10), p.823-831

2017

Volltextzugriff (PDF)

Anti‐viral therapy can be delayed or avoided in a significant proportion of HBeAg‐negative Caucasian patients in the Grey Zone

Alimentary pharmacology & therapeutics, 2018-05, Vol.47 (10), p.1397-1408

2018

Volltextzugriff (PDF)

Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti‐viral therapy with an interferon‐free regimen

Alimentary pharmacology & therapeutics, 2017-04, Vol.45 (8), p.1156-1161

2017

Volltextzugriff (PDF)

Donor and Recipient IL28B Polymorphisms in HCV‐Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation

American journal of transplantation, 2011-05, Vol.11 (5), p.1051-1057

2011

Volltextzugriff (PDF)

Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection

Revista Española de Sanidad Penitenciaria, 2017-12, Vol.19 (3), p.87-97

2017

Volltextzugriff (PDF)

Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C

American journal of transplantation, 2014-02, Vol.14 (2), p.375-383

2014

Volltextzugriff (PDF)

Systematic review with meta‐analysis: neuroimaging in hepatitis C chronic infection

Alimentary pharmacology & therapeutics, 2018-05, Vol.47 (9), p.1238-1252

2018

Volltextzugriff (PDF)

Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2011-01, Vol.33 (1), p.138-148

2011

Volltextzugriff (PDF)

Screnning of viral hepatitis in mental disorder patients: Psiqui-Clinic Programme

European psychiatry, 2022-06, Vol.65 (S1), p.S480-S481

2022

Volltextzugriff (PDF)

Significant early and long-term improvement of neuropsychiatry symptomatology in HCV-infected patients after viral eradication with DAA

European psychiatry, 2022-06, Vol.65 (S1), p.S238-S239

2022

Volltextzugriff (PDF)

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

Journal of viral hepatitis, 2012-05, Vol.19 (s2), p.1-26

2012

Volltextzugriff (PDF)

Cyclosporine A or Tacrolimus for Hepatitis C Recurrence? An Old Debate

American journal of transplantation, 2011-08, Vol.11 (8), p.1559-1560

2011

Volltextzugriff (PDF)

849 INTERPLAY BETWEEN BASIC RESIDUES OF HEPATITIS C VIRUS GLYCOPROTEIN E2 WITH LIPOPROTEINS, VIRAL RECEPTORS AND NEUTRALIZING ANTIBODIES

Journal of hepatology, 2012-04, Vol.56, p.S331-S331

2012

Volltextzugriff (PDF)

Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct‐acting antiviral therapy—authors' reply

Alimentary pharmacology & therapeutics, 2017-06, Vol.45 (12), p.1559-1560

2017

Volltextzugriff (PDF)

Early changes in brain structure, functional connectivity and neuropsychiatric symptoms after HCV infection cure with direct-acting antivirals

European psychiatry, 2021-04, Vol.64 (S1), p.S254-S254

2021

Volltextzugriff (PDF)

Clinical and virological outcomes of hepatitis B virus inactive carriers and gray zone patients: a comparative analysis using current EASL and AASLD Guidelines criteria

Journal of hepatology, 2017, Vol.66 (1), p.S254-S255

2017

Volltextzugriff (PDF)

Hepatitis C Virus Compartmentalization and Infection Recurrence after Liver Transplantation

American journal of transplantation, 2009-07, Vol.9 (7), p.1591-1601

2009

Volltextzugriff (PDF)

781 IDENTIFICATION OF HEPATITIS C VIRUS (HCV) GLYCOPROTEIN E2 DOMAINS AND RESIDUES RESPONSIBLE FOR INTERACTION WITH HEPARAN SULFATE

Journal of hepatology, 2011-03, Vol.54, p.S314-S314

2011

Volltextzugriff (PDF)

Severe Hepatitis C Recurrence as a Risk Factor for Opportunistic Infections in Liver Transplant Recipients

Transplantation proceedings, 2018-06, Vol.50 (5), p.1437-1443

2018

Volltextzugriff (PDF)

Natural History of Chronic Hepatitis B Virus Infection in Inactive Carriers and in “Gray Zone” Patients

Journal of hepatology, 2016, Vol.64 (2), p.S369-S370

2016

Volltextzugriff (PDF)

Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2016-02, Vol.43 (3), p.364-374

2016

Volltextzugriff (PDF)

Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals

Journal of hepatology, 2017, Vol.66 (1), p.S318-S318

2017

Volltextzugriff (PDF)

Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth

Journal of hepatology, 2017, Vol.66 (1), p.S20-S20

2017

Volltextzugriff (PDF)

Significant incidence of psyquiatric disorders despite rapid and positive impact of direct acting antivirals on quality of life

Journal of hepatology, 2017, Vol.66 (1), p.S715-S715

2017

Volltextzugriff (PDF)

1 – 25 von 285

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(278)
Mit Volltextzugriff
(263)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

HCV‐Positive Donor Organs in Solid Organ Transplantation: “Mind the Gap!”

Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension

Anti‐viral therapy can be delayed or avoided in a significant proportion of HBeAg‐negative Caucasian patients in the Grey Zone

Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti‐viral therapy with an interferon‐free regimen

Donor and Recipient IL28B Polymorphisms in HCV‐Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation

Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection

Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C

Systematic review with meta‐analysis: neuroimaging in hepatitis C chronic infection

Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C

Screnning of viral hepatitis in mental disorder patients: Psiqui-Clinic Programme

Significant early and long-term improvement of neuropsychiatry symptomatology in HCV-infected patients after viral eradication with DAA

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

Cyclosporine A or Tacrolimus for Hepatitis C Recurrence? An Old Debate

849 INTERPLAY BETWEEN BASIC RESIDUES OF HEPATITIS C VIRUS GLYCOPROTEIN E2 WITH LIPOPROTEINS, VIRAL RECEPTORS AND NEUTRALIZING ANTIBODIES

Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct‐acting antiviral therapy—authors' reply

Early changes in brain structure, functional connectivity and neuropsychiatric symptoms after HCV infection cure with direct-acting antivirals

Clinical and virological outcomes of hepatitis B virus inactive carriers and gray zone patients: a comparative analysis using current EASL and AASLD Guidelines criteria

Hepatitis C Virus Compartmentalization and Infection Recurrence after Liver Transplantation

781 IDENTIFICATION OF HEPATITIS C VIRUS (HCV) GLYCOPROTEIN E2 DOMAINS AND RESIDUES RESPONSIBLE FOR INTERACTION WITH HEPARAN SULFATE

Severe Hepatitis C Recurrence as a Risk Factor for Opportunistic Infections in Liver Transplant Recipients

Natural History of Chronic Hepatitis B Virus Infection in Inactive Carriers and in “Gray Zone” Patients

Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C

Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals

Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth

Significant incidence of psyquiatric disorders despite rapid and positive impact of direct acting antivirals on quality of life

Suchergebnisse filtern